Developing and testing a novel self-guided digital therapeutic solution for preventing stammering in children: incorporating latest research on early detection and progress evaluation using real-world data

开发和测试一种新颖的自我引导数字治疗解决方案，用于预防儿童口吃：结合使用真实世界数据进行早期检测和进展评估的最新研究

• 批准号: 10072187
• 金额: $ 31万
• 依托单位: RESPIRA LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072187
• 关键词: Developing; testing; novel; self; guided

**Need**Stammering typically begins between the ages of 2 and 6, and becomes chronic in adolescence for 25% of affected children. It affects 8% of children globally and 2% of teenagers and adults. Early detection of stammering in young children is crucial for effective intervention and treatment. However, currently available tools for detecting stammering are designed for speech and language therapists (SLTs), and long waiting lists to access SLTs can worsen mental health challenges.**Project Opportunity**Respira, a UK SME, aims to develop in this project a new therapeutic solution for early detection and progress evaluation of stammering in children who stammer that parents, guardians and caregivers (PGCs) can use and interpret without SLT support.With the support of a previous Innovate UK grant, Respira built BeneTalk: a digital therapeutic solution to provide accessible, effective, and ongoing support for chronic stammering. This project aims to develop a new solution, by leveraging existing BeneTalk expertise/framework/capabilities, thus expanding Respira's market share.The diagnostic and evaluation tools developed in the project will allow also Respira to assess the effectiveness of this project by using real-world data for evidence generation.The project will have a transformative effect on Respira's technical and commercial impact, increasing its TAM, and on the UK economy in terms of taxes and employment.**State-of-the-Art**There are no digital therapeutic solutions available for PGCs of children who stammer (CWS). The current standard of care is face-to-face therapy sessions with SLTs, which are limited or expensive, and without support outside the clinic or post-therapy. This project will be compatible with both the Lidcombe Programme and Palin Parent-Child Interaction Therapy, which are standard treatment practices. This will increase the adoption of this project and achieve better therapy outcomes.**Wider Impact**The project will transform the lives of CWS and PGCs by democratising access to speech therapy: It will improve mental health by addressing anxiety, depression, and other mental health conditions that affect both.Developing and commercialising this project will provide a cost-effective solution to tackle inequality due to the "postcode" lottery affecting UK speech therapy pathways. This project will enable the delivery of speech therapy in the home and reduce the need to travel to face-to-face appointments and follow-ups, which is estimated to be 1500 times greener than the standard of care. Developing such a humanitarian business benefits the UK economy due to high-skill jobs created, taxes collected, and national branding.

**需要**结结巴巴通常在2至6岁之间开始，并且在25％的受影响儿童中在青春期变得慢性。它影响了全球8％的儿童，有2％的青少年和成人。幼儿结结巴巴的早期发现对于有效的干预和治疗至关重要。但是，目前可用于言语和语言治疗师（SLT）设计的目前可用于检测结结巴巴的工具，访问SLT的长期等待列表可能会加剧心理健康的挑战。 Respira的先前Innovate Grant的支持，建立了Benetalk：一种数字治疗解决方案，可为慢性结结巴巴提供易于访问，有效和持续的支持。 This project aims to develop a new solution, by leveraging existing BeneTalk expertise/framework/capabilities, thus expanding Respira's market share.The diagnostic and evaluation tools developed in the project will allow also Respira to assess the effectiveness of this project by using real-world data for evidence generation.The project will have a transformative effect on Respira's technical and commercial impact, increasing its TAM, and on the UK economy in terms of taxes and就业。当前的护理标准是用SLT进行的面对面治疗课程，其有限或昂贵，并且在治疗后没有支持。该项目将与Lidcombe计划和Palin亲子互动疗法兼容，这是标准治疗方法。这将增加该项目的采用并取得更好的治疗结果。该项目将使家中言语治疗的交付，并减少前往面对面的约会和随访的需求，估计比护理标准绿色1500倍。由于创造的高技能工作，收集的税收和国家品牌，发展这种人道主义业务受益于英国经济。